Lodo Therapeutics Enters $970 Million Multi-Target Collaboration With Genentech

Reston – June 26, 2018 – Cooley advised Lodo Therapeutics Corporation on its $969 million strategic drug discovery collaboration with Genentech, a member of the Roche Group. Cooley partner Kenneth Krisko led the team advising Lodo on the transaction.

Under the terms of the agreement, Genentech will utilize Lodo’s proprietary genome mining and biosynthetic cluster assembly platform to identify novel molecules with therapeutic potential against multiple disease-related targets. Lodo is eligible to receive research, development and commercialization milestone payments of up to $969 million and tiered royalties on sales of certain products.

“We are excited to work with Genentech in their quest to discover novel, next-generation natural products derived from the microbiome of the soil using this innovative platform developed by Lodo,” said Sean Brady, co-founder of Lodo Therapeutics, in a news release.

Rather than relying on culturing known strains of bacteria, Lodo Therapeutics’ genome-based approach leverages the power of microbial evolution to identify novel, naturally occurring compounds that have therapeutic potential in the treatment of cancer and drug-resistant bacterial infections. This approach is expected to reduce the time and cost of drug discovery.

In 2016, Cooley advised Lodo on its $17 million Series A funding round.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.